Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Corporate Finance

Vator Securities provides an extensive range of capital markets and advisory services to cutting-edge public and private growth companies with an emphasis on the Life Sciences, Medical Technology and Diagnostics sectors.

We apply an entrepreneurial spirit to everything we do. We build long lasting relationships with our clients based on mutual trust. Vator Securities executes on opportunities that accelerate growth for its client companies whilst delivering results to the firm’s sophisticated investor clientele.

Vator Securities is led by experienced professionals who have between 15 to 25 years of capital market and advisory experience from some of the world’s most prominent investment banks. Our service offering includes:

  • ​Pre-IPO Financing
  • IPOs and Secondaries
  • Capital Markets Advisory
  • Strategic Advisory
  • Equity Research

Vator Securities distinguishes itself by the firm’s ability to raise capital from traditional institutional investors, as well as from its proprietary global network of family offices and high net worth investors. The unique network of investors implies that Vator Securities can source capital irrespective of financial market sentiments and create liquidity in the stock post IPO.

At Vator Securities every project is more than a single transaction. We specialize in providing partnerships where we work long-term with the client and support the value creation of a company long before a transaction commences. We focus on building a long-term strategy for our clients by guiding and consulting extensively throughout the entire life cycle – from idea to completion, but also through follow-ups and post transaction consulting and support.

AlzeCure

200 MSEK | IPO | Q4 2018

Sole global coordinator and bookrunner

Nanoform

71 MSEK | Private placement | Q2 2018

Sole bookrunner

AlzeCure

40 MSEK | Private placement | Q2 2018

Sole bookrunner

Immunovia

324 MSEK | Direct share issue | Q2 2018

Sole bookrunner

Plastics Unbound

50 MSEK | Private placement | Q2 2018

Sole bookrunner

Ascelia Pharma

60 MSEK | Private placement | Q1 2018

Sole bookrunner

Bio-Works

80 MSEK | IPO | Q4 2017

Sole bookrunner

IRRAS

334 MSEK | IPO | Q4 2017

Financial advisor

SenzaGen

90,1 MSEK | IPO | Q3 2017

Sole bookrunner

TerraNet

100 MSEK | IPO | Q2 2017

Sole bookrunner

AlzeCure

70 MSEK | Private placement | Q2 2017

Sole bookrunner

Biovica

60 MSEK | IPO | Q1 2017

Sole bookrunner

Acarix

140,4 MSEK | IPO | Q4 2016

Sole bookrunner

Immunovia

189,9 MSEK + 28,7 MSEK | Q3 2016

Private placement & rights issue

Sole bookrunner

Nilar

50 MSEK | Private placement | Q2 2016

Sole bookrunner

Xbrane Biopharma

100 MSEK | IPO Q4 | 2015

Sole bookrunner

Vikingaliv

113,6 MSEK | Private placement | Q2 2015

Sole bookrunner